-
Antiphospholipid syndrome in the era of COVID-19 – Two sides of a coin Autoimmun. Rev. (IF 13.6) Pub Date : 2024-04-09 Naim Mahroum, Mona Habra, Mohamad Aosama Alrifaai, Yehuda Shoenfeld
In addition to the respiratory symptoms associated with COVID-19, the disease has consistently been linked to many autoimmune diseases such as systemic lupus erythematous and antiphospholipid syndrome (APS). APS in particular was of paramount significance due to its devastating clinical sequela. In fact, the hypercoagulable state seen in patients with acute COVID-19 and the critical role of anticoagulant
-
What have we learned on pre, very early, and early systemic sclerosis microcirculatory pathophysiology? A scoping review Autoimmun. Rev. (IF 13.6) Pub Date : 2024-04-09 Joana Caetano, Luís Monteiro Rodrigues, José Delgado Alves
Microvascular dysfunction is an early event in the pathogenesis of systemic sclerosis (SSc). The objective of this scoping review is to update the current information and the level of knowledge about the mechanisms of microvascular dysfunction in pre-SSc, very early diagnosis of SSc (VEDOSS) and early SSc. A PubMed® database search allowed us to include original data from full-length articles in English
-
Exposure to different occupational chemicals and clinical phenotype of a cohort of patients with systemic sclerosis Autoimmun. Rev. (IF 13.6) Pub Date : 2024-04-08 Mayka Freire, Bernardo Sopeña, Arturo González-Quintela, Alfredo Guillén del Castillo, Eduardo Callejas Moraga, Gema M. Lledó-Ibañez, Manuel Rubio-Rivas, Luis Trapiella, Ana Argibay, Carles Tolosa, Begoña Marí Alfonso, Jose Antonio Vargas-Hitos, Xavier Pla Salas, Cristina González-Echávarri, Antonio-J Chamorro, Isabel Perales Fraile, Andrés González García, Gloria de la Red Bellvis, David Bernal Bello
-
Factors associated with incident cardiovascular disease in patients with rheumatoid arthritis: A scoping review Autoimmun. Rev. (IF 13.6) Pub Date : 2024-04-04 Yasaman Hajiesmaeili, Preeti Tamhankar, Saverio Stranges, Lillian Barra
Rheumatoid arthritis (RA) is the most common form of autoimmune inflammatory arthritis and is associated with various comorbidities including cardiovascular disease (CVD). This scoping review summarizes the current evidence on longitudinal cohort studies assessing potential factors associated with the incidence of cardiovascular events among patients with RA. Scopus, PubMed, Ovid MEDLINE and Cochrane
-
From autoantibody test results to decision making: Incorporating likelihood ratios within medical practice Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-31 Kevin D. Deane, Lieve Van Hoovels, Veena E. Joy, Nina Olschowka, Xavier Bossuyt
-
The ‘whole landscape’ of research on systemic sclerosis over the past 73 years Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-29 Meng-Di Zhang, Wan-Ying Huang, Jia-Yuan Luo, Rong-Quan He, Zhi-Guang Huang, Jian-Di Li, Fang Qin, Gang Chen, Ling Lei
This study aimed to analyse existing research on systemic sclerosis (SSc) conducted over the past 73 years to develop an essential reference for a comprehensive and objective understanding of this field of inquiry. Using the Web of Science Core Collection, PubMed, and Scopus databases as data sources for the bibliometric analysis, we searched for published literature related to SSc over the past 73 years
-
Prevalence of anti-Ro52-kDa/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: Data from a French cohort, a systematic review and meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-28 Marie-Elise Martel, Amélie Leurs, David Launay, Hélène Behal, Aurélien Chepy, Aurore Collet, Sébastien Sanges, Eric Hachulla, Sylvain Dubucquoi, Luc Dauchet, Vincent Sobanski
-
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-27 Maurizio Bruschi, Andrea Angeletti, Marco Prunotto, Pier Luigi Meroni, Gian Marco Ghiggeri, for the Zeus consortium, Gabriella Moroni, Renato Alberto Sinico, Franco Franceschini, Micaela Fredi, Augusto Vaglio, Andrea Cavalli, Leonardo Scapozza, Jigar J. Patel, John C. Tan, Ken C. Lo, Lorenzo Cavagna, Andrea Petretto, Federico Pratesi, Paola Migliorini, Francesco Locatelli, Giulia Pazzola, Giampaola
Deposition of autoantibodies in glomeruli is a key factor in the development of lupus nephritis (LN). For a long time, anti-dsDNA and anti-C1q antibodies were thought to be the main cause of the kidney damage. However, recent studies have shown that the list of autoantibidies that have renal tropism and deposit in the kidney in LN is increasing and the link between anti-dsDNA and renal pathology is
-
Redox mechanisms in autoimmune thyroid eye disease Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-26 Francesco Buonfiglio, Katharina A. Ponto, Norbert Pfeiffer, George J. Kahaly, Adrian Gericke
-
The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-22 Fabio Salvatore Macaluso, Flavio Caprioli, Laura Benedan, Cristina Bezzio, Roberto Caporali, Alberto Cauli, Maria Sole Chimenti, Francesco Ciccia, Salvatore D'Angelo, Massimo Claudio Fantini, Stefano Festa, Florenzo Iannone, Ennio Lubrano, Paolo Mariani, Claudio Papi, Giuseppe Provenzano, Daniela Pugliese, Antonio Rispo, Simone Saibeni, Carlo Salvarani, Angela Variola, Mariangela Zenga, Alessandro
Spondyloarthritis (SpA) is the most frequent extraintestinal manifestation in patients with inflammatory bowel diseases (IBD). When IBD and spondyloarthritis coexist, musculoskeletal and intestinal disease features should be considered when planning a therapeutic strategy. Treatment options for IBD and SpA have expanded enormously over the last few years, but randomized controlled trials with specific
-
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-17 Xiaoying Sun, Ziyang Cui, Qingyun Wang, Liu Liu, Xiaojie Ding, Jiao Wang, Xiaoce Cai, Bin Li, Xin Li
Formation of anti-drug antibodies (ADAs) against biologics is an important cause of psoriasis treatment failure. This study aimed to summarize the characteristics of ADAs formation under different biological therapies and the influence of ADAs on the clinical effects and safety of biologics in patients with psoriasis. PubMed, Embase, and Web of Science databases were searched from their inception to
-
Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: A systematic review and meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-16 Huang Kuang, Nan Jiang, Xiao-Yu Jia, Zhao Cui, Ming-Hui Zhao
Anti-glomerular basement membrane (GBM) disease is a small-vessel vasculitis that represents the most aggressive form of autoimmune glomerulonephritis. The study aimed to investigate the prevalence, clinical characteristics, risk factors, and outcomes of anti-GBM disease through a systematic review and meta-analysis involving 47 studies with 2830 patients. The overall incidence of anti-GBM disease
-
Cerebral vasculitis as a clinical manifestation of neurosarcoidosis: A scoping review Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-16 Yaroslav Winter, Sergiu Groppa, Timo Uphaus, Erik Ellwardt, Sven Fuest, Sven Meuth, Stefan Bittner, Eyad Hayani
The occurrence of cerebral vasculitis in individuals with neurosarcoidosis (NS) is considered to be rare. Although the number of relevant publications has increased in recent years, evidence is mostly limited to case reports. To obtain a better understanding of this rare and severe manifestation of disease, we carried out a scoping review on cerebral vasculitis in patients diagnosed with NS. The results
-
Structural cell heterogeneity underlies the differential contribution of IL-17A, IL-17F and IL-23 to joint versus skin chronic inflammation Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-15 Marie Robert, Pierre Miossec
The current therapeutic strategy used in immune-mediated inflammatory diseases (IMIDs) primarily targets immune cells or associated-pathways. However, recent evidence suggests that the microenvironment modulates immune cell development and responses. During inflammation, structural cells acquire a pathogenetic phenotype and the interactions with immune cells are often greatly modified. Understanding
-
Clinical phenotype of AAV, anti-GBM disease and double-positive patients after SARS-CoV-2 vaccination Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-13 Yisha Li, Jie Wang, Shuang Liang, Yan Zhang, Zhe Feng, Guangyan Cai
-
Ethnicity also influences the clinical heterogeneity of mixed connective tissue disease of childhood onset: The French West Indies experience Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-05 Arthur Felix, Fabienne Louis-Sidney, Christophe Deligny, Benoit Suzon
-
Herpes vaccine, splenectomy, and thymectomy associated with autoimmune diseases and the kaleidoscope of autoimmunity Autoimmun. Rev. (IF 13.6) Pub Date : 2024-02-20 Abihai Lucas Hernández, Ora Shovman, Pnina Langevitz, Yehuda Shoenfeld
-
Reprint of “Residual pain in rheumatoid arthritis: Is it a real problem?” Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-24 Piercarlo Sarzi-Puttini, Margherita Zen, Federico Arru, Valeria Giorgi, Ernest A. Choy
Pain is a significant issue in rheumatoid arthritis (RA) and can have a negative impact on patients' quality of life. Despite optimal control of inflammatory disease, residual chronic pain remains a major unmet medical need in RA. Pain in RA can be secondary to inflammation but can also generate neuroendocrine responses that initiate neurogenic inflammation and enhance cytokine release, leading to
-
Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-18 Ricardo Rojo, Jaime Calvo Alén, Álvaro Prada, Santiago Valor, Garbiñe Roy, Marcos López-Hoyos, Ricard Cervera, Paloma Sánchez Mateos, Aurora Jurado Roger
-
Childhood mixed connective tissue disease at disease onset: Evidence from a systematic review Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-06 Alberto Terminiello, Edoardo Marrani, Ilaria Pagnini, Ilaria Maccora, Valerio Maniscalco, Sarah Abu Rumeileh, Maria Vincenza Mastrolia, Gabriele Simonini
Objective Childhood Mixed Connective Tissue Disease (cMCTD) is the rarest pediatric connective tissue disease that includes features of systemic lupus erythematosus, polymyositis/dermatomyositis, juvenile idiopathic arthritis, and systemic sclerosis, identified by Sharp in 1972 and whose diagnosis remains challenging. This systematic review aims to identify clinical features at the onset of cMCTD and
-
Animal models unraveling the complexity of vitiligo pathogenesis Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-05 Prashant Giri, Dharm Desai, Mitesh Dwivedi
Vitiligo is a chronic skin condition marked by the gradual loss of pigmentation, leading to the emergence of white or depigmented patches on the skin. The exact cause of vitiligo remains not entirely understood, although it is thought to involve a blend of genetic, autoimmune, and environmental factors. While there is currently no definitive cure for vitiligo, diverse treatments exist that may assist
-
Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-31 Victoria Liedtke, Michael Stöckle, Kerstin Junker, Dirk Roggenbuck
Benign prostatic hyperplasia (BPH) is considered as an age-related disease of men with an unknown etiopathophysiology. Chronic inflammation has been proposed as one of the major pathophysiological mechanisms. There is growing evidence for the involvement of autoimmune responses in an inflammatory setting in the prostate. Patients with autoimmune diseases show a significantly elevated prevalence of
-
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-03 Elvira Favoino, Marcella Prete, Vasiliki Liakouli, Patrizia Leone, Adriana Sisto, Luca Navarini, Marta Vomero, Francesco Ciccia, Piero Ruscitti, Vito Racanelli, Roberto Giacomelli, Federico Perosa
Pre-capillary pulmonary arterial hypertension (PAH) is hemodynamically characterized by a mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, pulmonary capillary wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) > 2. PAH is classified in six clinical subgroups, including idiopathic PAH (IPAH) and PAH associated to connective tissue diseases (CTD-PAH), that will be the main object
-
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-01 Cecilia B. Chighizola, Rohan Willis, Gabriella Maioli, Savino Sciascia, Laura Andreoli, Olga Amengual, Massimo Radin, Maria Gerosa, Tatsuya Atsumi, Guilherme de Jesus, Laura Trespidi, D. Ware Branch, Roberto Caporali, Danieli Andrade, Robert Roubey, Michelle Petri, Maria Laura Bertolaccini
In antiphospholipid syndrome (APS), the risk of clinical manifestations increases with higher titers of antiphospholipid antibodies (aPL). Despite the adoption of aPL titers in the classification approach to aPL-positive subjects, the value of longitudinal monitoring of those titers in the follow-up is still debated, being well studied only in systemic lupus erythematosus (SLE). The literature suggests
-
Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-31 L. Ondrejčáková, M. Gregová, K. Bubová, L. Šenolt, K. Pavelka
Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of
-
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-29 Altijana Hromić-Jahjefendić, Kenneth Lundstrom, Muhamed Adilović, Alaa A.A. Aljabali, Murtaza M. Tambuwala, Ángel Serrano-Aroca, Vladimir N. Uversky
The complicated relationships between autoimmunity, COVID-19, and COVID-19 vaccinations are described, giving insight into their intricacies. Antinuclear antibodies (ANA), anti-Ro/SSA, rheumatoid factor, lupus anticoagulant, and antibodies against interferon (IFN)-I have all been consistently found in COVID-19 patients, indicating a high prevalence of autoimmune reactions following viral exposure.
-
Metal-induced autoimmunity in neurological disorders: A review of current understanding and future directions Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-28 Geir Bjørklund, Aleksandra Buha Đorđević, Halla Hamdan, David R. Wallace, Massimiliano Peana
Autoimmunity is a multifaceted disorder influenced by both genetic and environmental factors, and metal exposure has been implicated as a potential catalyst, especially in autoimmune diseases affecting the central nervous system. Notably, metals like mercury, lead, and aluminum exhibit well-established neurotoxic effects, yet the precise mechanisms by which they elicit autoimmune responses in susceptible
-
Comprehensive reproductive healthcare for women with immune-mediated inflammatory diseases: Addressing rheumatoid arthritis, spondyloarthritis and inflammatory bowel disease through life's stages Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-22 Laura Andreoli, Ilaria Guadagni, Giovanna Picarelli, Mariabeatrice Principi
Immuno-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, spondyloarthritis, and inflammatory bowel disease are characterised by pathophysiological mechanisms wherein the immune system erroneously targets the body's own tissues. This review explores the heightened vulnerability of women with IMIDs, influenced by hormonal modulators like estrogen and progesterone. The challenges this
-
Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-21 Benjamin Thoreau, Luc Mouthon
Pulmonary arterial hypertension (PAH), corresponding to group 1 of pulmonary hypertension classification, is a rare disease with a major prognostic impact on morbidity and mortality. PAH can be either primary in idiopathic and heritable forms or secondary to other conditions including connective tissue diseases (CTD-PAH). Within CTD-PAH, the leading cause of PAH is systemic sclerosis (SSc) in Western
-
Non-invasive imaging in antiphospholipid syndrome to assess subclinical coronary artery disease Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-20 Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Juan Carlos Solis-Poblano, Karla Godinez-Bolaños, Mario García-Carrasco, Ricardo O. Escárcega, Socorro Méndez-Martínez, Luis Javier Jara-Quezada
Antiphospholipid antibody syndrome (usually named antiphospholipid syndrome, APS) is an autoimmune disorder seen mainly in young people. Clinically, APS is described by pregnancy complications and/or a hypercoagulable state, including the venous or arterial vasculature, and strongly related to antiphospholipid antibodies. Although several cardiac manifestations have been involved with APS, and accelerated
-
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-20 Virginia Solitano, Paola Facheris, Magnus Petersen, Ferdinando D'Amico, Michela Ortoncelli, Daniel Aletaha, Pablo A. Olivera, Thomas Bieber, Sofia Ramiro, Subrata Ghosh, Maria Antonietta D'Agostino, Britta Siegmund, Isabelle Chary-Valckenaere, Ailsa Hart, Lorenzo Dagna, Fernando Magro, Renaud Felten, Paulo Gustavo Kotze, Vipul Jairath, Antonio Costanzo, Silvio Danese
Background and Aims The Pharmacovigilance Risk Assessment Committee (PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases (IMID). Use of these medications in individuals aged 65 and older, those at high cardiovascular risk, active or former long-term smokers, and those with increased cancer risk should be considered
-
Adipose failure through adipocyte overload and autoimmunity Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-13 Nicola Susca, Patrizia Leone, Marcella Prete, Susanna Cozzio, Vito Racanelli
-
Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-13 Federica Davanzo, Maria Rita Marchi, Luca Iorio, Michela Bortoli, Andrea Doria, Roberto Padoan
Monoclonal antibodies targeting type 2 inflammation are promising treatments for eosinophilic-associated diseases. There is growing interest in the potential benefits of combining two biologics to treat patients with poorly controlled conditions. We present a case of a 54-year-old female patient affected with a relapsing-refractory ANCA myeloperoxidase positive eosinophilic granulomatosis with polyangiitis
-
Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-05 Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven, Anneke van der Walt, Vilija Jokubaitis, Mastura Monif
-
Dysfunction of the glymphatic system and sleep disturbance in rheumatoid arthritis and musculoskeletal pain: A gap related to pain becoming chronic Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-05 Isadora de Oliveira Barbosa, André Pontes-Silva, José Mário Prati
Abstract not available
-
Does a window of opportunity for rheumatoid arthritis-associated interstitial lung disease exist? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-10 Mitsuhiro Akiyama, Waleed Alshehri, Yuko Kaneko
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammatory synovitis, eventually leading to joint destruction. Remarkable advancements in the emergence of molecular targeted therapies and the treatment strategy based on treat-to-target have made it possible for patients to lead their daily lives without disabilities. Specifically, early diagnosis and appropriate treatment
-
Machine learning application in autoimmune diseases: State of art and future prospectives Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-09 Maria Giovanna Danieli, Silvia Brunetto, Luca Gammeri, Davide Palmeri, Ilaria Claudi, Yehuda Shoenfeld, Sebastiano Gangemi
Autoimmune diseases are a group of disorders resulting from an alteration of immune tolerance, characterized by the formation of autoantibodies and the consequent development of heterogeneous clinical manifestations. Diagnosing autoimmune diseases is often complicated, and the available prognostic tools are limited. Machine learning allows us to analyze large amounts of data and carry out complex calculations
-
Vitamin D deficiency and non-infectious uveitis: A systematic review and Meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-03 William Rojas-Carabali, Juan Sebastián Pineda-Sierra, Carlos Cifuentes-González, María Sofía Morales, Paula Tatiana Muñoz-Vargas, Luisa Fernanda Peña-Pulgar, María Alejandra Fonseca-Mora, Danna Lesley Cruz, Ikhwanuliman Putera, Lucia Sobrin, Rupesh Agrawal, Alejandra de-la-Torre
Background Vitamin D plays a critical role in immunomodulation, and its deficiency is implicated in the pathogenesis of several autoimmune diseases. Nevertheless, its relationship with non-infectious uveitis (NIU), an inflammatory ocular disorder, remains inconclusive. Methods A systematic search was conducted in three databases from database inception until May 8, 2023, to investigate the potential
-
Global, regional, and national burden of inflammatory bowel disease and its associated anemia, 1990 to 2019 and predictions to 2050: An analysis of the global burden of disease study 2019 Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-03 Song Wang, Zhixia Dong, Xinjian Wan
Aim Inflammatory bowel disease (IBD) exhibited a global increase in incidence over the past decade. Understanding global burden of IBD can offer valuable insights for shaping future management strategies. We aimed to provide a comprehensive assessment of global burden of IBD from 1990 to 2019 and predictions to 2050. Methods Data on prevalence, incidence, Disability-Adjusted Life Years (DALYs), Years
-
-
From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-30 Boualem Sendid, Marjorie Cornu, Camille Cordier, Julie Bouckaert, Jean Frederic Colombel, Daniel Poulain
Anti-Saccharomyces cerevisiae antibodies (ASCA) are human antibodies that can be detected using an enzyme-linked immunosorbent assay involving a mannose polymer (mannan) extracted from the cell wall of the yeast S. cerevisiae. The ASCA test was developed in 1993 with the aim of differentiating the serological response in two forms of inflammatory bowel disease (IBD), Crohn's disease and ulcerative
-
Invariant natural killer T cells in autoimmune cholangiopathies: Mechanistic insights and therapeutic implications Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-30 Roopa Hebbandi Nanjundappa, Kun Shao, Prasanna Krishnamurthy, M. Eric Gershwin, Patrick S.C. Leung, Channakeshava Sokke Umeshappa
Invariant natural killer T cells (iNKT cells) constitute a specialized subset of lymphocytes that bridges innate and adaptive immunity through a combination of traits characteristic of both conventional T cells and innate immune cells. iNKT cells are characterized by their invariant T cell receptors and discerning recognition of lipid antigens, which are presented by the non-classical MHC molecule
-
Relevance of vein wall thickness in Behcet's disease: A systematic review and meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-29 Mira Merashli, Tommaso Bucci, Jose Delgado-Alves, Paul R.J. Ames
Objectives To perform a meta-analysis on articles evaluating the common femoral vein wall thickness (VWT) in Behcet's disease and its possible clinical, laboratory and treatment correlates (BD). Methods Systematic search of EMBASE and PubMed databases from inception to October 2023; we employed random effect meta-analyses for continuous outcomes. Results The meta-analysis included 9 case-control and
-
Brain-regional characteristics and neuroinflammation in ME/CFS patients from neuroimaging: A systematic review and meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-26 Jin-Seok Lee, Wakiro Sato, Chang-Gue Son
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition characterized by an elusive etiology and pathophysiology. This study aims to evaluate the pathological role of neuroinflammation in ME/CFS by conducting an exhaustive analysis of 65 observational studies. Four neuroimaging techniques, including magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS)
-
Takotsubo syndrome occurring in systemic diseases: A French multicenter retrospective case-control study and literature review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-26 Julien Culerrier, Benjamin Terrier, Matthieu Groh, Marilucy Lopez-Sublet, Benjamin De Sainte Marie, Géraldine Falgarone, Olivier Lidove, Patrick Mercie, Luc Mouthon, Christophe Meune, Robin Dhote
Objective Describe the characteristics of patients presenting with TTS during the course of a broad spectrum of systemic diseases, in comparison to classic TTS. Methods French multicenter retrospective case-control study completed by a literature review. Results 19 new cases were included in the study. The literature review identified 25 previously published cases. Among the 44 patients, 41 were females
-
Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-25 Georgios Gakis, Ioannis Angelopoulos, Ioannis Panagoulias, Athanasia Mouzaki
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). RRMS is the most common type, with the majority of patients eventually progressing to SPMS, in which neurological development is constant
-
New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-24 Denise Donzella, Elisa Bellis, Paola Campisi, Gloria Crepaldi, Valeria Data, Paolo Dapavo, Claudia Lomater, Elena Marucco, Marta Saracco, Mariele Gatto, Annamaria Iagnocco
Objective To report cases of new onset sarcoidosis upon biologic (bDMARDs) treatment administration in patients with seronegative inflammatory arthritis in a real-life cohort, alongside a systematic literature review (SLR) on this topic. Methods We performed a retrospective analysis on clinical records of patients with seronegative arthritis followed up in a monocentric cohort who underwent bDMARDs
-
Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-13 Ricardo Rojo, Jaime Calvo Alén, Álvaro Prada, Santiago Valor, Garbiñe Roy, Marcos López-Hoyos, Ricard Cervera, Paloma Sánchez Mateos, Aurora Jurado Roger
-
Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-11 Fabiola Atzeni, Fabio Cacciapaglia, James Galloways, Andreina Manfredi, Garifallia Sakellariou, Sam Norton, Elisa Gremese, Francesca Romana Spinelli, Ombretta Viapiana, Matteo Piga, Gian Luca Erre, Elena Bartoloni Bocci
Aim To evaluate the impact of selective cytotoxic T-lymphocyte-associated protein 4 (CTLA-4Ig) compared to tumor necrosis factor inhibitors (TNFi) on cardiovascular (CV) clinical and laboratory outcomes in patients with rheumatoid arthritis (RA). Methods We performed a prospective observational multicenter study of RA patients included in the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)”
-
Serum calprotectin is a marker of disease activity in Giant cell arteritis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-24 Antoine Saut, Marie-Hélène Paclet, Candice Trocmé, Bertrand Toussaint, Alexis Bocquet, Laurence Bouillet, Athan Baillet
Abstract not available
-
Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-24 Thomas Khoo, Hector Chinoy
The discovery of autoantibodies directed against the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) enzyme has defined a sub-set of immune-mediated necrotising myopathy (IMNM) which is strongly associated with exposure to statin medications. Although understanding of anti-HMGCR IMNM has grown considerably with the reporting of multiple cohorts in North America, Europe, Asia and Oceania, there remain
-
SLE classification criteria: Is “The causality principle” integrated and operative – and do the molecular and genetical network, on which criteria depend on, support the definition of SLE as “a one disease entity” – A theoretical discussion Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-24 Ole Petter Rekvig
Molecular and cellular aspects of the autoimmune pathophysiology in SLE is linked to the “The causality principle”. SLE Classification Criteria identify per definition disease measures (here: synonymous with classification criteria), but not diagnostic criteria within a classical framework. These two mostly theoretical criteria collections represent a salient conflict between phenomenology and the
-
Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-19 Ozgur C. Kilinc, Serdal Ugurlu
Background and objectives Dermatomyositis is chronic autoimmune disease primarily affecting skin and muscles. Antibodies are key players of pathogenesis and are in strong correlation with distinct clinical phenotypes. We present a case and a comprehensive review of the literature on dermatomyositis patients with Anti TIF1 antibodies. Methods PubMed and Web of Science databases were reviewed. 166 articles
-
Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-17 Massimo Radin, Irene Cecchi, Francesca Crisafulli, Evandro Mendes Klumb, Guilherme Ramires de Jesús, Marcela Ignacchiti Lacerda, Miguel Ángel Saavedra, Geraldine Vanessa Reyes-Navarro, Luca Iaccarino, Maddalena Larosa, Gabriella Moroni, Francesco Tamborini, Dario Roccatello, Laura Andreoli, Savino Sciascia, Cecilia Beatrice Chighizola
Background Complement levels have been proposed as candidate biomarkers of disease activity and obstetric risk in systemic lupus erythematosus (SLE) pregnancies, but their reliability has been questioned due to the physiologic fluctuations of complement during gestation. Thus, this network meta-analysis aimed at assessing the clinical significance of complement fluctuations in lupus pregnant women
-
A comprehensive review of the advances in neuromyelitis optica spectrum disorder Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-16 Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven, Anneke van der Walt, Vilija Jokubaitis, Mastura Monif
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing neuroinflammatory autoimmune astrocytopathy, with a predilection for the optic nerves and spinal cord. Most cases are characterised by aquaporin-4-antibody positivity and have a relapsing disease course, which is associated with accrual of disability. Although the prognosis in NMOSD has improved markedly over the past few years owing
-
From inflammation to renal fibrosis: A one-way road in autoimmunity? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-15 Dario Roccatello, Hui-Yao Lan, Savino Sciascia, Sanjeev Sethi, Alessia Fornoni, Richard Glassock
Renal fibrosis is now recognized as a main determinant of renal pathology to include chronic kidney disease. Deposition of pathological matrix in the walls of glomerular capillaries, the interstitial space, and around arterioles predicts and contributes to the functional demise of the nephron and its surrounding vasculature. The recent identification of the major cell populations of fibroblast precursors
-
Should we use nintedanib as early therapy in patients with SSc-ILD? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-14 Elisabetta Zanatta, Beatrice Moccaldi, Gabriella Szucs, Paolo Spagnolo
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease, where a significant proportion of patients develop interstitial lung disease (ILD), which is the major cause of mortality. In recent years, the diagnosis of SSc-ILD has improved a lot, and caring rheumatologists, together with pulmonologists, regularly screen and follow the development and course of ILD. Considerable progress has also
-
Aberrant N-myristoylation as a prelude to autoimmune manifestations in patients with SHOC2 mutations Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-02 Donato Rigante, Chiara Leoni, Roberta Onesimo, Valentina Giorgio, Valentina Trevisan, Giuseppe Zampino
Abstract not available
-
Idiopathic inflammatory myopathies – The burden of disease: Cohort analysis focusing on damage and comorbidities Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-29 Ana Campar, Inês Alves, Ana Martins da Silva, Fátima Farinha, Carlos Vasconcelos
Introduction/Background Idiopathic Inflammatory Myopathies (IIM) continue to be a major clinical challenge worldwide. The exact aetiopathogenesis of this chronic and disabling disease remains elusive, preventing the development of novel and effective therapeutic strategies and leading to a high incidence of damage. The complexity of treating these diseases is even greater due to the numerous comorbidities
-
Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-22 Maria Infantino, Silvia Foddai, Mariangela Manfredi, Maurizio Benucci, Massimo Radin, Irene Cecchi, Alice Barinotti, Ofir Aluf, Elena Rubini, Rahbari Elnaz, Elisa Menegatti, Dario Roccatello, Savino Sciascia
Abstract not available